The impact of sharing results of a randomized breast cancer clinical trial with study participants.

Abstract:

BACKGROUND:There has been growing interest in providing clinical trial participants with study results yet only limited information exists regarding the process and impact of sharing results. We sought to evaluate patient perceptions of how results had been shared from a large randomized cooperative group trial, and the impact of learning results. PATIENTS AND METHODS:A subset of women who participated in NCCTG 9831 (A Phase III Trial of Adjuvant Chemotherapy with or without Trastuzumab for Women with HER2-positive Breast Cancer) were mailed surveys after the preliminary study results were released to the public and mailed to participants. RESULTS:One hundred and 67 of 228 surveys sent (73%) were returned; 61% reported receiving trastuzumab on study; 4% reported recurrent disease. Ninety-five percent of participants were glad they received results; 81% were satisfied with how results were shared; 23% were more anxious after learning the results. Sixty-nine percent correctly interpreted the results. Logistic regression revealed that satisfaction with the process of receiving results was associated with satisfaction with treatment (P = 0.04), and increased anxiety was associated with dissatisfaction with treatment (0.02), incorrect interpretation of results (0.04), and not having received trastuzumab (P < 0.0001). CONCLUSION:Sharing results directly with study participants is met with overwhelmingly favorable responses from patients, although some may not initially understand the findings. The potential for increased anxiety should be considered, and psychosocial support may be required by some. A plan to share results should be routinely and prospectively considered in the design of cancer clinical trials.

authors

Partridge AH,Wolff AC,Marcom PK,Kaufman PA,Zhang L,Gelman R,Moore C,Lake D,Fleming GF,Rugo HS,Atkins J,Sampson E,Collyar D,Winer EP

doi

10.1007/s10549-008-0057-7

subject

Has Abstract

pub_date

2009-05-01 00:00:00

pages

123-9

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

115

pub_type

杂志文章,随机对照试验
  • Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

    abstract::Inflammatory breast cancer (IBC) is a rare and aggressive disease. Previous studies have shown that among patients with stage III breast cancer, IBC is associated with a worse prognosis than noninflammatory breast cancer (non-IBC). Whether this difference holds true among patients with stage IV breast cancer has not b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3436-x

    authors: Fouad TM,Kogawa T,Liu DD,Shen Y,Masuda H,El-Zein R,Woodward WA,Chavez-MacGregor M,Alvarez RH,Arun B,Lucci A,Krishnamurthy S,Babiera G,Buchholz TA,Valero V,Ueno NT

    更新日期:2015-07-01 00:00:00

  • Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.

    abstract::A review of the literature finds that women diagnosed with breast cancer, who were on an aspirin regimen, experienced a decreased risk of distant metastases and death. Several recent studies have reported an improvement in overall survival in colorectal cancer patients who harbored mutations in the oncogene PIK3CA and...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3729-8

    authors: Turturro SB,Najor MS,Ruby CE,Cobleigh MA,Abukhdeir AM

    更新日期:2016-02-01 00:00:00

  • Pharmacology of aminoglutethimide: structure/activity relationships and receptor interactions.

    abstract::The structure/activity relationships for inhibition of aromatase and cholesterol side-chain cleavage enzyme (CSCC) by aminoglutethimide and some of its analogues are reviewed. Although more effective against aromatase than CSCC, aminoglutethimide markedly inhibits both enzymes. Optimal competitive antagonism of aromat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:

    authors: Nicholls PJ,Daly MJ,Smith HJ

    更新日期:1986-01-01 00:00:00

  • Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients.

    abstract::Our aim was to develop an accurate diagnostic system using gene expression analysis by means of DNA microarray for prognosis of node-negative and estrogen receptor (ER)-positive breast cancer patients in order to identify a subset of patients who can be safely spared adjuvant chemotherapy. A diagnostic system comprisi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1145-z

    authors: Naoi Y,Kishi K,Tanei T,Tsunashima R,Tominaga N,Baba Y,Kim SJ,Taguchi T,Tamaki Y,Noguchi S

    更新日期:2011-08-01 00:00:00

  • Ha-ras rare alleles in breast cancer susceptibility.

    abstract::Over the last several years, evidence has accumulated to support the idea that rare Ha-ras polymorphisms are associated with inherited susceptibility to certain human cancers. A recent epidemiologic study conducted at our institution found a significant association specifically with breast cancer, although the mechani...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00694750

    authors: Conway K,Edmiston S,Fried DB,Hulka BS,Garrett PA,Liu ET

    更新日期:1995-07-01 00:00:00

  • Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.

    abstract:PURPOSE:The RAS family comprises three proto-oncogenes (H-RAS, K-RAS, and N-RAS) and is among the most widely studied of oncogenes. The present study aimed at investigating the clinical relevance of mRNA levels of the three isoforms in a large group of breast cancer patients with a long-term follow-up. METHODS:198 pre...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05474-8

    authors: Banys-Paluchowski M,Milde-Langosch K,Fehm T,Witzel I,Oliveira-Ferrer L,Schmalfeldt B,Müller V

    更新日期:2020-01-01 00:00:00

  • FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

    abstract::FOXP3-expressing T regulatory lymphocytes (Tregs) have been described as putative mediators of immune tolerance, and thus facilitators of tumor growth. When found in association with various malignancies, Tregs are generally markers of poor clinical outcome. However, it is unknown whether they are also associated with...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2556-4

    authors: Lal A,Chan L,Devries S,Chin K,Scott GK,Benz CC,Chen YY,Waldman FM,Hwang ES

    更新日期:2013-06-01 00:00:00

  • A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

    abstract:PURPOSE:The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-018-4770-6

    authors: O'Shaughnessy J,DeMichele A,Ma CX,Richards P,Yardley DA,Wright GS,Kalinsky K,Steis R,Diab S,Kennealey G,Geschwindt R,Jiang W,Rugo HS

    更新日期:2018-08-01 00:00:00

  • Normal epithelial antigens recognized by GB3 and GB5 are diminished in intraductal and lost in infiltrating human breast carcinomas.

    abstract::GB3 and GB5 are mouse monoclonal antibodies raised against human amnion. GB3 detects the epidermal basement membrane, and GB5 reacts with the junctional substances between the epithelial cells. These two antibodies were studied on breast tissues by indirect immunofluorescence. All (n = 8) of the normal mammary glandul...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01807700

    authors: Yeh CJ,Hsi BL,Ettore F

    更新日期:1986-01-01 00:00:00

  • Participation and satisfaction with surgical treatment decision-making in breast cancer among Chinese women.

    abstract:PURPOSE:To report Chinese women's preferred and perceived participation in breast cancer treatment decision making (TDM), describe influences on women's participation preference and participation congruence (PC) (correspondence between preferred and actual amount of participation in TDM), and explore subsequent satisfa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/A:1024568732213

    authors: Lam W,Fielding R,Chan M,Chow L,Ho E

    更新日期:2003-07-01 00:00:00

  • Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis.

    abstract:BACKGROUND:The aims of this study were to define the distribution of caveolin 2 (CAV2) in frozen and formalin fixed, paraffin embedded (FFPE) normal breast samples and the significance of CAV2 expression in breast cancer. METHODS:Caveolin 2 distribution in frozen and paraffin-embedded whole tissue sections of normal b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9718-1

    authors: Savage K,Leung S,Todd SK,Brown LA,Jones RL,Robertson D,James M,Parry S,Rodrigues Pinilla SM,Huntsman D,Reis-Filho JS

    更新日期:2008-07-01 00:00:00

  • The additional cancer yield of clinical breast examination in screening of women at hereditary increased risk of breast cancer: a systematic review.

    abstract::Women at hereditary increased risk of breast cancer are subjected to frequent clinical breast examination (CBE) and radiological evaluation of the breasts. This review appraises the additional cancer yield by CBE in screening of women at increased risk of breast cancer who are also subjected to frequent radiological e...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-014-3074-8

    authors: Roeke T,van Bommel AC,Gaillard-Hemmink MP,Hartgrink HH,Mesker WE,Tollenaar RA

    更新日期:2014-08-01 00:00:00

  • Isolation and characterization of a breast progenitor epithelial cell line with robust DNA damage responses.

    abstract::We report the establishment of a breast epithelial cell model that undergoes growth arrest at different stages of the cell cycle depending upon the DNA damaging agents encountered. Primary breast epithelial cells from normal reductive mammoplasty were grown in low-calcium culture medium. Free-floating cells under this...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9173-4

    authors: Shen KC,Miller F,Tait L,Santner SJ,Pauley R,Raz A,Tainsky MA,Brooks SC,Wang YA

    更新日期:2006-08-01 00:00:00

  • Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status.

    abstract::WWOX is a cancer gene, spanning the common chromosomal fragile site 16D. Genomic and expression aberrations affecting this gene and locus are common in various neoplasias including breast cancer. The aim of the present study was to evaluate the relationship between WWOX expression at the protein level with respect to ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-004-1474-x

    authors: Nunez MI,Ludes-Meyers J,Abba MC,Kil H,Abbey NW,Page RE,Sahin A,Klein-Szanto AJ,Aldaz CM

    更新日期:2005-01-01 00:00:00

  • Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.

    abstract:PURPOSE:Although breast cancer in young women accounts for <10% of diagnoses annually, tumors in young patients exhibit more aggressive characteristics and higher mortality rates. Determination of the frequency of germline mutations in cancer predisposition genes is needed to improve the understanding of breast cancer ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4291-8

    authors: Rummel SK,Lovejoy L,Shriver CD,Ellsworth RE

    更新日期:2017-08-01 00:00:00

  • Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization.

    abstract::Macroautophagy (autophagy), a process for lysosomal degradation of organelles and long-lived proteins, has been linked to various pathologies including cancer and to the cellular response to anticancer therapies. In the human estrogen receptor positive MCF7 breast adenocarcinoma cell line, treatment with the endocrine...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9873-4

    authors: Qadir MA,Kwok B,Dragowska WH,To KH,Le D,Bally MB,Gorski SM

    更新日期:2008-12-01 00:00:00

  • Reversed urban-rural differences in breast cancer mortality (China, 2002-2008).

    abstract::The purpose of this study was to examine the urban-rural difference in breast cancer mortality between 2002 and 2008 in China. A longitudinal analysis of mortality data was performed. Mortality data were extracted from Chinese Health Statistics Yearbook. Linear regression was used to examine the statistical significan...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1276-2

    authors: He M,Guo Q,Hu G

    更新日期:2011-02-01 00:00:00

  • Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.

    abstract::This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer. This was a multicenter, open-label, randomized study. Primary endpoint was a non-in...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-010-1332-y

    authors: Masuda N,Iwata H,Rai Y,Anan K,Takeuchi T,Kohno N,Takei H,Yanagita Y,Noguchi S

    更新日期:2011-04-01 00:00:00

  • Quality of life of breast cancer survivors after a recurrence: a follow-up study.

    abstract::Previous studies on breast cancer recurrence provide a mixed picture of the quality of life of women following a recurrence. To clarify the picture, the present study addresses some previous methodological concerns by offering a multidimensional assessment with follow-up, a matched comparison group of disease-free sur...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000041580.55817.5a

    authors: Oh S,Heflin L,Meyerowitz BE,Desmond KA,Rowland JH,Ganz PA

    更新日期:2004-09-01 00:00:00

  • Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.

    abstract:BACKGROUND:Given its high recurrence risk, guidelines recommend systemic therapy for most patients with early-stage triple-negative breast cancer (TNBC). While some clinicopathologic factors and tumor-infiltrating lymphocytes (TILs) are known to be prognostic in patients receiving chemotherapy, their prognostic implica...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4499-7

    authors: Leon-Ferre RA,Polley MY,Liu H,Gilbert JA,Cafourek V,Hillman DW,Elkhanany A,Akinhanmi M,Lilyquist J,Thomas A,Negron V,Boughey JC,Liu MC,Ingle JN,Kalari KR,Couch FJ,Visscher DW,Goetz MP

    更新日期:2018-01-01 00:00:00

  • Breast cancer vascularity: color Doppler sonography and histopathology study.

    abstract::In this prospective study, the authors examined 50 patients with breast tumors (malignant, n = 32; benign, n = 18) to investigate the correlation between color Doppler flow mapping and histopathological findings and to evaluate the clinical significance of color Doppler mapping. Among the 32 patients with breast cance...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806510

    authors: Lee WJ,Chu JS,Huang CS,Chang MF,Chang KJ,Chen KM

    更新日期:1996-01-01 00:00:00

  • Higher stromal expression of transforming growth factor-beta type II receptors is associated with poorer prognosis breast tumors.

    abstract::Transforming growth factor-beta (TGFB) is a potent inhibitor of normal epithelial cell proliferation, and may be one of the regulatory factors that are perturbed during tumor development. While many tumor cell lines no longer respond to the inhibitory effects of TGFB due to a reduction or absence of the type II recept...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1023918026437

    authors: Barlow J,Yandell D,Weaver D,Casey T,Plaut K

    更新日期:2003-05-01 00:00:00

  • Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration.

    abstract::Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase: ST6GalNAc I, which catalyzes the transfer of a sialic acid residue in alpha2,6-linkage to the...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-004-3137-3

    authors: Julien S,Lagadec C,Krzewinski-Recchi MA,Courtand G,Le Bourhis X,Delannoy P

    更新日期:2005-03-01 00:00:00

  • Intra-operative ultrasound versus wire-guided localization in the surgical management of non-palpable breast cancers: systematic review and meta-analysis.

    abstract:INTRODUCTION:The current standard of treatment for non-palpable breast cancers is wire-guided localization (WGL). WGL has its drawbacks and alternatives such as radio-guided surgery (RGL) and intra-operative ultrasound (IOUS) have been developed. The clinical effectiveness of all forms of RGL has been assessed against ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-013-2639-2

    authors: Ahmed M,Douek M

    更新日期:2013-08-01 00:00:00

  • High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.

    abstract:PURPOSE:Cyclin D1 has a central role in cell cycle control and is an important component of estrogen regulation of cell cycle progression. We have previously shown that high cyclin D expression is related to aggressive features of ER-positive but not ER-negative breast cancer. The aims of the present study were to vali...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4294-5

    authors: Ahlin C,Lundgren C,Embretsén-Varro E,Jirström K,Blomqvist C,Fjällskog M-

    更新日期:2017-08-01 00:00:00

  • Breast cancer prevention through modulation of endogenous hormones.

    abstract::The use of exogenous sex-steroids for hormonal contraception is important to the way of life of many modern women. The widespread use of hormonal contraceptives represents a unique opportunity to have a substantial positive impact on women's health. The observation that users of oral combination type contraceptives ha...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666430

    authors: Spicer DV,Pike MC

    更新日期:1993-11-01 00:00:00

  • Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells.

    abstract::The majority of breast cancer deaths are because of ineffective treatment of metastatic disease. We previously identified a subpopulation of cells in human breast cancer cell lines that demonstrate high activity of aldehyde dehydrogenase (ALDH) and high expression of CD44. These ALDH(hi)CD44(+) cells displayed enhance...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1692-y

    authors: Croker AK,Allan AL

    更新日期:2012-05-01 00:00:00

  • EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.

    abstract::EMSY is a putative oncogene amplified in a minority of breast carcinomas, its protein product interacts with and transcriptionally silences BRCA2. We hypothesized that breast tumors from BRCA2 mutation carriers would be less likely than other familial breast cancers to exhibit EMSY amplification. As EMSY is located on...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1380-y

    authors: Bane AL,Mulligan AM,Pinnaduwage D,O'Malley FP,Andrulis IL

    更新日期:2011-06-01 00:00:00

  • MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.

    abstract:PURPOSE:miRNAs have been linked to chemosensitivity of breast cancer cells in vitro. In patients, however, there is no clinically validated method for predicting chemotherapy response. The aim of this study was to assess whether (I) a specific pattern of miRNA expression in pretherapeutic biopsies can predict response ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4132-9

    authors: Raychaudhuri M,Bronger H,Buchner T,Kiechle M,Weichert W,Avril S

    更新日期:2017-04-01 00:00:00

  • Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study.

    abstract::Five-year breast cancer survivors, diagnosed after 65 years of age, may develop more incident comorbidities than similar populations free of cancer. We investigated whether older breast cancer survivors have a similar comorbidity burden 6-15 years after cancer diagnosis to matched women free of breast cancer at start ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3021-8

    authors: Jordan JH,Thwin SS,Lash TL,Buist DS,Field TS,Haque R,Pawloski PA,Petersen HV,Prout MN,Quinn VP,Yood MU,Silliman RA,Geiger AM

    更新日期:2014-07-01 00:00:00